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Context: Craniopharyngiomas are often associated with an unfavorable prognosis, but data on
their long-term consequences are sparse.
Objective: The aim of the study was to identify markers of recurrence and factors associated with
compromised social rehabilitation and altered quality of life in a large cohort of patients with
either childhood-onset (CO) or adult-onset craniopharyngioma.
Methods:Retrospective analysiswas performed for 171 patients treated for craniopharyngioma in
two academic centers in France between 1972 and 2009. For each subject, data were collected
concerning clinical presentation, imaging features, visual sequelae, endocrine and metabolic im-
pact, treatment modalities (surgery, radiotherapy), recurrence-free survival rate, and social inser-
tion, as well as answers to the WHO-QOL BREF questionnaire.
Results:A total of 65 CO and 106 adult-onset patients were reviewed. If COwas diagnosed before
the age of 10 yr, this was associated with a higher incidence of obesity, blindness, and panhypo-
pituitarism, and only 40.7% of subjects had adequate work or school attendance compared to
72.4% of patients with later disease onset. Initial symptoms of intracranial hypertension (SIHT),
pterional surgery, and multiple surgery were associated with obesity and poorer social insertion.
No determinant of quality of life was identified. In the subgroup of patients treated in the 1990s
and later, the progression rate was 59.4% in patients with residual tumor on magnetic resonance
imaging comparedwith a 19.8% recurrence rate in the groupwith apparently complete resection.
Recurrence/progression correlates significantly with male gender, early onset (before 10 yr), and
SIHT, but only SIHT at presentation remained a significant predictor with multivariate analysis.
Conclusions: Craniopharyngioma continues to be associated with severe outcomes. Higher mor-
bidity rates are found in patients with early-onset disease (before 10 yr), initial SIHT, or in whom
pterional surgerywas required.Markers of recurrence are difficult to identify, with SIHT being the
most powerful predictor. (J Clin Endocrinol Metab 97: 1258–1267, 2012)
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Craniopharyngiomas account for 2–5% of all pri-mary intracranial tumors (1). They can occur at
any age but aremore commonly diagnosed during child-
hood or adolescence (1, 2). They are histologically be-
nign tumors, traditionally believed to arise from rem-
nants of Rathke’s pouch in the craniopharyngeal duct
(3, 4). Despite their benign histological appearance, cra-
niopharyngiomas are associated with increased mortal-
ity, as well as marked physical and cognitive sequelae
adversely affecting quality of life (QoL) as a result of
their proximity to the visual pathways, the pituitary
gland, and the hypothalamus (2, 5).
Optimal treatment remains controversial. Gross total
resection is associated with lower recurrence rates, but it
carries a risk of damage to the visual pathways, the pitu-
itary, or the hypothalamus (6–9). On the other hand, in-
complete resection is associated with a high recurrence
rate, further morbidity and mortality from tumor re-
growth, aswell as risk for repeated surgery. Another strat-
egy is partial tumor removal supplemented by subsequent
radiotherapy, either given as adjuvant therapy or at the
time of relapse. Combined therapy may provide a better
outcome and social rehabilitation score (10–13), despite
concerns about potential adverse effects of irradiation,
mainly risk of cognitive repercussions and radiation-in-
duced secondary neoplasia (14, 15).
Because craniopharyngiomas are rare tumors and large
cohorts are difficult to constitute, previous attempts to
identify factors for prognosis or recurrence with a good
correlation to long-term morbidity have failed to provide
consistent markers. Moreover, adjuvant radiotherapy is
frequently performedafter partial tumor removal,making
it difficult to collect data and conclusions about the nat-
ural history of the disease (12).
In the present study, we analyzed the clinical presenta-
tion, recurrence rate, long-term morbidity, and QoL in a
large cohort of patients with childhood-onset (CO) and
adult-onset (AO) craniopharyngiomas, followed over a
long period to determine predictors of relapse, compro-
mised social reinsertion, and impaired QoL.
Subjects and Methods
Study population
Retrospective analysis was performed of 171 cases of cranio-
pharyngiomas treated at the endocrinology department of the
Groupe Hospitalier de la Pitie´-Salpeˆtrie`re-Paris and at the en-
docrinology and pediatric departments of theCentreHospitalier
de l’Universite´ de Rennes. Subjects were identified from the gen-
eral database of each department. Data were reviewed for all
patients classified as being diagnosed with craniopharyngioma
between 1972 and 2009. The diagnosis of craniopharyngioma
was largely based on histopathological confirmation, but for
three patients it was based upon characteristic features seen on
neuroimaging.
Patients were separated into CO and AO craniopharyngi-
omas as is the standard practice. CO subjects were further
stratified into two equivalent groups, aged either under 10 yr
or between 10 and 18 yr at presentation, because younger CO
subjects in the cohort appeared to present significant differ-
ences in terms of clinical presentation, recurrence rate, and
long-term morbidity.
Analysis was performed for each group, and a comparison
wasmade betweenCOandAO. For specific comparison of long-
term morbidity and social insertion between CO and AO pa-
tients, the five COpatients aged under 18 yr at the last follow-up
were excluded, enabling us to correlate comparable criteria, and
thus limiting the cohort to 166patients for final analysis of social
rehabilitation.
Further analysis was also made for the subgroup of CO and
AOdiagnosed after 1990 (n123; 34CO,89AO).The aimwas
to evaluate modern management of craniopharyngiomas and to
validate certain risk factors for long-term morbidity since new
surgical techniques and radiological evaluation bymagnetic res-
onance imaging (MRI)was introduced in the 1990s. The specific
impact of the presence of residual tumor was studied in this
subgroup to limit bias resulting from more precise modern im-
aging techniques.
Clinical data and definitions
Residual tumorwasdefinedas thepresenceof tumor reported
by the radiologist based on the MRI or computed tomography
scan obtained 3 to 6 months postoperatively. Diagnosis of re-
currencewas based upondetection of tumor or significant tumor
growth on imaging more than 6 months after initial complete or
partial surgical resection, with or without associated signs and
symptoms. Time to recurrence was calculated from the date of
initial surgery. Intracranial hypertensionwas diagnosed if severe
hydrocephalus or symptoms of increased intracranial pressure
were present.
At the time of medical assessment, pituitary functions were
evaluated, and endocrine deficiencies were determined accord-
ing to classic endocrine standards. Furthermore, almost all de-
ficient patients received appropriate hormone replacement ther-
apy. Panhypopituitarism was defined if three or more anterior
pituitarydeficitswerepresent.Apatientwas considered epileptic
if at least one seizure occurred and antiepileptic medication was
prescribed. Blindness was defined as visual acuity of 1/10 or less
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in both eyes. Complete social rehabilitation was pronounced if
subjects attended a regular school or worked in an institution
without any program for persons with special needs or limita-
tions. Inability to work was recorded if the patient was institu-
tionalizedordeclaredunfit forwork (handicap80%according
to French social security standards).
QoL assessmentwas performed using theWHO-QOLBREF,
a 26-item universally approved World Health Organization
(WHO) QoL questionnaire that explores a subject’s physical
health (seven items), psychological health (six items), social re-
lations (three items), and environment (eight items), with two
final questions to assess the patient’s perception of global QoL
through individual scoring of overall appreciation of life and
general sense of personal well-being. Answers to each question
were coded from 1 to 5, summed, and placed on a scale from 0
to 100, with 100 representing the highest perception or level of
QoL (16, 17). Surveyswere sent bymail to all living patients, and
answers were obtained from 97 patients (56.7% of the cohort).
Statistical analysis
All analyses were performed using SAS version 9.2 (SAS In-
stitute, Cary, NC), and a two-sided level of P  0.05 was con-
sidered statistically significant. Statistical calculations were
based on the number of patients with data available for this
evaluation. Comparisons of discrete variables were performed
using a 2 test or Fisher’s exact test, and continuous variables
were compared using the Mann-Whitney U test. Survival and
recurrence-free curves were generated using the Kaplan-Meier
method, and differences in recurrence rates between the various
subgroups were analyzed using Cox models. Analyses of recur-
rence were adjusted based on the presence of residual tumor.
Logistic regressions were used to determine odds ratios for each
outcome, with adjustment for follow-up, center (Rennes or
Paris), and gender. Linear regression analysis was performed to
determine the relationshipbetweenWHO-QOLBREF items and
clinical presentation and management.
Results
Clinical presentation
Clinical features at presentation as reported in themed-
ical files aredisplayed inTable1.Meanage at presentation
was respectively 5.5, 12.5, and 38.0 yr in each subgroup,
with a range from 1.4 to 78.1 yr for the entire cohort.
Almost two thirds of patients suffered from headaches,
with similar figures forCOandAOpatients. Visual acuity
and/or field impairment were more frequent in patients
with CO younger than 10 yr (P  0.01). Intracranial hy-
pertension was significantly more prevalent when cranio-
pharyngiomawas diagnosed before 10 yr, compared with
CO 10–18 yr and AO patients. In contrast, hormonal-
related symptomsweremore common in theCO10–18 yr
subgroup and represent themost common presenting sign
in this age group. Polyuria/polydipsia and proven central
diabetes insipidus were reported in 13% of patients at
presentation and were similarly distributed among the
three age groups.
Tumor site and management
Only seven patients (4.09%) had a tumor localized to
the pituitary not extending beyond the sellar margins
(Table 1). Most patients with CO had both intra- and
extrasellar craniopharyngiomas, and most craniophar-
yngiomas were smaller than 2 cm. On the other hand,
adults hadmostly extrasellar-only tumors and thatwere
less than 2 cm. More CO patients had surgery per-
formed before 1990, resulting in a shorter follow-up for
AO craniopharyngiomas in our cohort.Most CO andAO
patients had pterional surgery. The transphenoidal ap-
proachwas used for only one COpatient younger than 10
yr, in 20%of CO patients 10–18 yr of age, and in 30%of
adults. Radiotherapy was used significantly more often in
CO than in AO patients. Radiotherapy was conventional
fractionated external beam irradiation in almost all cases
but two inwhich stereotactic radiosurgerywasperformed.
Residual tumor based on imaging at 3 to 6 months was
described in one third of patients.
Recurrences
In our cohort, the total recurrence rate, either recur-
rence after complete resection or progression after partial
resection, was 35.7%, with 43.9% in the CO subgroup
and 30.2% in adults. Moreover, in the subgroup of pa-
tients treated in the 1990s and later, the progression rate
was 59.4% inpatientswith residual tumor comparedwith
a19.8%recurrence rate in thegroupwithapparently com-
plete resection (Fig. 1A). Most patients relapsed within 5
yr of initial surgery (median time to recurrence, 3.5 yr),
although tumor recurred in one patient 19 yr after initial
resection. Recurrence was more frequent in patients with
CO younger than 10 yr (Fig. 1B), those with intracranial
hypertension at presentation (Fig. 1C), and in male sub-
jects (Fig. 1D). After adjustment for the presence of a re-
sidual tumor, male gender and intracranial hypertension
remained significantly associated with a higher risk of re-
currence. Recurrence was significantly more frequent in
CO patients within 5 yr and remained significant after
adjustment for the presence of a residual tumor (P 
0.020, data not shown). The relationbetweenmale gender
and intracranial hypertension was no longer significant
after further adjustment for intracranial hypertension.No
difference was noted between recurrence-free survival
rates according to tumor location (intrasellar, extrasellar,
or both) or tumor size.
Long-term sequelae
Results for long-term sequelae for all adult patients are
displayed in Table 2. Panhypopituitarism and diabetes in-
sipidusweremore frequent in CO than in AO craniophar-
yngiomas (P  0.01). All patients with CO younger than
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10 yr had at least three anterior pituitary deficits, and all
but one had diabetes insipidus. In comparison, 73.8% of
AO patients had at least three anterior pituitary deficits,
and 68% had diabetes insipidus. The majority of patients
with CO craniopharyngiomas (78.5%) had received GH
supplementation during childhood.On the other hand, 37
patients had GH replacement during adulthood. Half of
the cohort had major visual acuity and/or field impair-
ment, with similar prevalence reported in all three age
groups. However, total blindness wasmore often encoun-
tered in those with CO less than 10 yr of age.
COpatients less than10 yr of age had ahigher bodymass
index (BMI) at final evaluation and were more frequently
obese compared with CO patients 10–18 yr old or AO pa-
tients (Table 2). Most of the weight gained was noted in the
first year after diagnosis or surgery, and there was only a
slight increase in BMI when comparing individual weight
andBMI at 1 and5 yr after surgery.Overall, long-termmor-
bidity improvedslightlyafter1990,withparticular improve-
ment in CO patients less than 10 yr old, whereas the rate of
blindness, epilepsy, and obesity fell (Supplemental Table 1,
published on The Endocrine Society’s Journals Online web
site at http://jcem.endojournals.org).
Functional outcome and QoL
Only 40.7%of COpatients younger than 10 yr had nor-
mal social insertion, rising to 53.8%when considering only
patients diagnosed after 1990. Social integration was better
inCOpatients ages 10–18 yr and inAOpatients, with com-
plete social rehabilitation in 68.7 and 75.5%, respectively.
Scores for the physical health, psychological health, and
social relationship components of the WHO-QOL BREF
were lower in patients with craniopharyngiomas than in the
general population (Table 3). Self-assessment of physical
TABLE 1. Presentation and treatment approach according to age at presentation
Aged under 10 yr
at presentation (A)
(n  33)
Aged between 10
and 18 yr at
presentation (B)
(n  32) P value
(A vs. B)
Aged above 18 yr
at presentation (C)
(n  106)
P value
(A  B
vs. C)na n (%) na n (%) na n (%)
Age (yr) at presentation, median
(1st to 3rd quartiles)
32b 5.5 (4–6) 32 12.5 (11–15) 106 38 (28–52)
Follow-up (months), median
(1st to 3rd quartiles)
33 202 (166–280) 32 208 (24–343.5) 0.97 97 96.5 (36–167) 0.01
Presenting clinical features
Headaches 30 19 (63.3%) 31 18 (58.1%) 0.67 100 61 (61.0%) 0.97
SIHT 30 13 (43.3%) 28 6 (21.4%) 0.08 100 15 (15.0%) 0.01
Polyuria/polydipsia and/or
proven diabetes insipidus
29 4 (13.8%) 28 4 (14.3%) 1 100 12 (12.0%) 0.71
Any endocrine
manifestation
33 16 (48.5%) 31 25 (80.6%) 0.01 106 51 (48.1%) 0.04
Visual acuity and/or field
impairment
28 23 (82.1%) 25 17 (68.0%) 0.23 101 72 (71.3%) 0.58
Location 32 29 0.21 105 0.01
Intrasellar 1 (3.1%) 3 (10.3%) 3 (2.9%)
Extrasellar 9 (28.1%) 8 (27.6%) 57 (54.3%)
Both 24 (75.0%) 18 (62.1%) 45 (42.9%)
Tumor size 20 18 0.04 73 0.19
1 cm 0 (0.0%) 3 (16.7%) 11 (15.1%)
1–2 cm 11 (55.0%) 12 (66.7%) 49 (67.1%)
2 cm or described as
large
9 (45.0%) 3 (16.7%) 13 (17.8%)
Decade of surgery 32 32 0.97 104 0.01
1970–1979 5 (15.6%) 4 (12.5%) 3 (2.8%)
1980–1989 9 (28.1%) 8 (25.0%) 13 (12.3%)
1990–1999 13 (40.6%) 15 (46.9%) 41 (38.7%)
2000–2009 5 (15.6%) 5 (15.6%) 47 (45.2%)
Residual tumor 31 11 (35.5%) 29 7 (24.1%) 0.34 103 33 (32.0%) 0.79
Surgical approach 30 30 0.10 105 0.01
Pterional 29 (96.7%) 24 (80.0%) 74 (70.5%)
Transphenoidal 1 (3.3%) 6 (20.0%) 31 (29.5%)
Radiotherapy 33 8 (24.2%) 30 9 (30.0%) 0.61 105 13 (12.4%) 0.02
Repeated surgery 33 4 (12.1%) 32 7 (21.9%) 0.34 106 6 (5.7%) 0.02
a Number of patients with available data for each item.
b Date of presentation is not known for one patient, but date of surgery is known.
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healthwas59.3%,comparedwith76.9%inthegeneralpop-
ulationand64.4%intheFrenchsubpopulationwithchronic
disease. Self-assessment of psychological healthwas 53.5%,
comparedwith 67.0% in the general population and 64.9%
in the French subpopulation with chronic disease. Self-as-
sessment of the social relationship item was 58.3%, com-
pared with 74.5% in the general population and 71.5% in
theFrenchsubpopulationwithchronicdisease.Thereported
QoL was similarly impaired in the three age groups of our
cohort of craniopharyngioma patients. No risk factor for
impairedQoLwas identified (Table 4).Neither presentation
characteristics nor tumor size, nor indeed therapeutic man-
agement were identified as predictive factors for poor QoL.
PatientswithnoQoLdatadidnotdiffer significantly in terms
ofageatpresentation,gender, intracranialhypertension,pte-
rional surgery, or recurrence rate.
Markers of long-term morbidity
Table 5 shows the odds ratios adjusted for gender,
center, and duration of follow-up of various long-term
morbidity outcomes associated with presenting clinical
features and management. CO in patients younger than
FIG. 1. A, Recurrence-free probability according to the presence of a residual tumor on postoperative imaging in 127 patients with
craniopharyngioma onset after 1990. B–D, Recurrence-free probability in CO (before 10 yr and 10–18 yr) and AO craniopharyngioma (B), in
patients with or without intracranial hypertension at presentation (C), and in male and female patients (D).
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10 yr is associated with a higher morbidity rate: more
blindness, partial or complete inability to work, and
obesity, as well as a lower level of social insertion.
Symptoms of intracranial hypertension (SIHT) at pre-
sentation are associated with a worse outcome, whereas
an only hormonal-related manifestation is associated
with a better outcome. Large tumors are associatedwith
panhypopituitarism, and there is a trend toward in-
crease blindness, inability to work, or obesity. Notice-
ably, the pejorative outcome of large tumors in terms of
obesity and social insertion fell after 1990 to the same
level as other tumors initially considered as large (Sup-
plemental Table 2).
Pterional surgery was associated with a worse outcome
than a transphenoidal approach in terms of panhypopitu-
itarism, blindness, social insertion, and obesity (Table 5).
Multiple surgery, the presence of a residual tumor, and ra-
diotherapy (almost exclusively a second-line treatment op-
tion in our cohort) were associated with increased overall
morbidity.
TABLE 3. Prevalence (%) of compromised social rehabilitation and impaired QoL assessed on WHO-QOL BREF at
final follow-up visit according to age at presentation in the 166 adults
Variables
Aged under 10 yr
at presentation (A)
(n  28)
Aged between 10
and 18 yr at
presentation (B)
(n  34) P value
(A vs. B)
Aged above 18 yr
at presentation (C)
(n  104)
P value
(A  B
vs. C)
French
population
with
chronic
diseasebna n (%) na n (%) na n (%)
Adequate social
insertion
27 11 (40.7%) 32 22 (68.7%) 0.03 102 77 (75.49%) 0.01
Inability to work 18 2 (11.1%) 21 1 (4.8%) 0.59 92 6 (6.52%) 1.00
WHO-QOL BREF, median
(quartiles)
Physical health 17 60.7 (57.1–67.9) 21 64.3 (53.6–71.4) 0.67 59 57.1 (42.9–67.9) 0.21 64.4%
Psychological
health
17 50.0 (45.8–54.2) 21 54.2 (41.7–62.5) 0.93 59 54.2 (41.7–62.5) 0.50 64.9%
Relationships 17 58.3 (41.7–91.7) 21 58.3 (41.7–75.0) 0.39 59 58.3 (50.0–66.7) 0.75 71.5%
Environment 17 68.7 (65.6–81.2) 21 65.6 (56.2–78.1) 0.51 59 68.7 (56.2–84.4) 0.92
a Number of patients with available data for each item.
b Ref. 18.
TABLE 2. Prevalence (%) of various morbidities at final follow-up according to age at presentation in the 166 adults
Variables
Aged under 10 yr
at presentation (A)
(n  28)
Aged between 10
and 18 yr at
presentation (B)
(n  34) P value
(A vs. B)
Aged above 18 yr
at presentation (C)
(n  104)
P value
(A  B
vs. C)na n (%) na n (%) na n (%)
Endocrine sequelae
At least three anterior
pituitary insufficiencies
28 28 (100.0%) 34 28 (82.3%) 0.03 103 76 (73.8%) 0.01
Diabetes insipidus 28 27 (96.4%) 34 28 (82.3%) 0.12 103 70 (68.0%) 0.01
Major visual acuity and
field impairment
26 14 (53.8%) 34 17 (50.0%) 0.77 102 49 (48.0%) 0.66
Blindness 27 10 (37.0%) 34 2 (5.9%) 0.01 103 14 (13.6%) 0.30
Epilepsy 28 9 (32.1%) 32 6 (18.7%) 0.23 103 16 (15.5%) 0.14
BMI (kg/m2), median
(1st–3rd quartiles)
28 33.1 (27.0–40.3) 33 26.2 (22.0–29.8) 0.01 94 27.7 (25.0–33.1) 0.80
25 5 (17.9%) 15 (45.4%) 0.01 21 (22.3%) 0.16
25–30 4 (14.3%) 10 (30.3%) 34 (36.2%)
30 19 (67.9%) 8 (24.2%) 39 (41.5%)
1-yr weight increase
1 SD or 3 kg/m2 22 12 (54.6%) 24 11 (45.8%) 0.56 70 36 (51.4%) 0.88
2 SD or 6 kg/m2 22 9 (40.9%) 24 5 (20.8%) 0.14 70 13 (18.6%) 0.14
5-yr weight increase
1 SD or 3 kg/m2 22 13 (59.1%) 24 14 (58.3%) 0.96 52 31 (59.6%) 0.93
2 SD or 6 kg/m2 22 9 (40.9%) 24 10 (41.7%) 0.96 52 16 (30.8%) 0.28
a Number of patients with available data for each item.
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Discussion
The present study showed in a large number of cases re-
inforcing data indicating that craniopharyngiomas re-
main associated with a severe outcome. In our cohort,
highermorbiditywas observed in patientswithCObefore
10 yr of age, initial SIHT, and in whom a pterional ap-
proach was required or performed. The characteristics of
our cohort are similar to those for other previously pub-
lished series of craniopharyngioma patients (2, 7, 8, 10–
12). The large number of patients in our cohort allowed
separate analysis and creation of subgroups according to
ageofonset, differentpatterns at clinical presentation, and
decade of diagnosis. The majority of patients with CO
younger than 10 yr had tumor-related symptoms at pre-
sentation. In particular, visual acuity and/or field impair-
ment were more frequent in patients with CO younger
than 10 yr, although the assessment of visual fields is dif-
ficult in young children and therefore is usually not per-
formed before surgery. In contrast, endocrine-related
symptoms were the main clinical presentation in patients
with CO at 10–18 yr of age. Previous studies have sug-
gested that SIHT were more frequent in younger children
(18, 19); we show that a prevalence of SIHT in children is
indeed observed for CO patients younger than 10 yr, but
not for CO patients 10–18 yr old.
Few studies have been designed for specific identifica-
tion of risk factors for specific long-term morbidity of
craniopharyngioma. de Vile et al. (20) identified certain
risk factors for increasedmorbidity: larger tumor size, hy-
pothalamic involvement (mainly obesity), and diagnosis
of craniopharyngioma before the age of 5 yr. A recent
report found that preoperative functional impairment in
80 children with craniopharyngiomas was a better pre-
dictor of postoperative outcome than clinical character-
istics such as age, sex, tumor size, tumor site, or presence
of hydrocephalus (21). We also identified differences in
long-term sequelae and social insertion according to var-
ious presenting features. SIHT at presentation is associ-
atedwith apoor outcome,whereas only hormonal-related
manifestations are associated with better recovery. A
young age at presentation was also associated with in-
creased morbidity, resulting in a high rate of partial or
TABLE 5. Risk of long-term morbidity and compromised functional outcome associated with presentation
characteristics, tumor size, and medical management in the 166 adults
Variables Panhypopituitarism Blindness
Partial or complete
inability to work
Normal social
insertion
Weight increase >2 SD
1 yr after surgery Obesity
Presentation
Aged under 10 yr NA 4.43 (1.52–12.90) 5.85 (0.43–80.20) 0.25 (0.10–0.64) 2.88 (0.97–8.58) 3.81 (1.51–9.62)
SIHT 1.70 (0.52–5.48) 2.02 (0.71–5.79) 2.30 (0.39–13.38) 0.32 (0.14–0.74) 4.11 (1.46–11.54) 3.17 (1.37–7.31)
Hormonal defect only at
presentation
0.38 (0.14–1.03) 0.19 (0.024–1.529) 0.71 (0.07–7.03) 3.57 (0.98–13.00) 0.18 (0.02–1.47) 0.48 (0.17–1.34)
Tumor size 2 cm or
described as large
9.20 (1.10–76.71) 4.00 (0.93–17.15) 4.23 (0.28–63.80) 0.58 (0.19–1.72) 1.51 (0.39–5.80) 1.83 (0.63–5.33)
Management
Pterional approach 3.15 (1.30–7.67) 7.40 (0.94–58.41) NA 0.17 (0.05–0.62) 6.42 (0.78–52.84) 6.15 (2.15–17.58)
Any recurrence 2.82 (0.96–8.25) 1.90 (0.70–5.21) 1.57 (0.20–12.17) 0.30 (0.14–0.67) 3.12 (1.11–8.71) 2.33 (1.10–4.92)
Multiple surgeries 3.33 (0.40–27.85) 1.72 (0.45–6.65) NA 0.61 (0.20–1.89) 1.96 (0.50–7.58) 1.42 (0.47–4.26)
Radiotherapy 0.77 (0.26–2.30) 0.80 (0.24–2.70) NA 0.88 (0.35–2.23) 4.04 (1.40–11.64) 1.79 (0.75–4.26)
Data are presented as follow-up length, center (Rennes-Paris), and gender-adjusted odds ratios (95% confidence interval). NA, Not applicable due
to quasi-complete separation.
TABLE 4. Associations between presentation characteristics, patient management, and the four QoL-related items
on the WHO-QOL BREF score
Variables
Physical health
(n  97)
Psychological
health (n  97)
Relationships
(n  97)
Environment
(n  97)
 P value  P value  P value  P value
Presentation characteristics
Aged under 10 yr 2.17 0.600 3.99 0.308 7.26 0.305 3.92 0.449
SIHT 5.94 0.125 4.35 0.228 5.39 0.419 3.02 0.533
Hormonal defect only at presentation 8.49 0.038 6.19 0.111 3.51 0.619 4.29 0.406
Tumor size 2 cm or described as large 1.94 0.700 0.95 0.843 1.89 0.832 4.41 0.466
Management
Pterional approach 0.50 0.895 4.54 0.192 4.48 0.484 1.89 0.683
Any recurrence 0.36 0.913 1.31 0.676 4.05 0.470 1.05 0.799
Multiple surgeries 2.39 0.658 0.73 0.886 1.22 0.895 2.62 0.697
Radiotherapy 2.68 0.534 1.16 0.773 10.22 0.160 0.22 0.966
Linear regression-derived  coefficients and P values after adjustment for follow-up length, center (Rennes-Paris), and gender are presented.
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complete inability to work. This emphasizes the difficulty
of management of craniopharyngiomas in younger chil-
dren, characterized in this population by larger tumors
and a high rate of intracranial hypertension, togetherwith
the consequence of early neurological damage on future
development. A previous study comparing CO and AO
craniopharyngiomas reported similar functional outcome
in both groups, but comparison between CO patients was
not performed (12). In our cohort, patients with CO less
than 10 yr old had a similar follow-up to individuals with
CO 10–18 yr old, whereas AO craniopharyngioma pa-
tients had shorter follow-up. Our results may therefore
depict a falsely less severe picture of AO craniopharyngi-
omas. However, the median duration of follow-up in AO
patients (8.5 yr) is longer than the median time of recur-
rence (3.5 yr), and the impact of a longer follow-up is thus
probably not the sole andmain explanation of the reduced
social outcome in CO patients. Noticeably, long-term
morbidity significantly improved after 1990 in patients
with CO less than 10 yr old.
The management of recurrent tumors is difficult, and
the optimal treatment modality remains a subject of de-
bate (22). Previous studies reported low rates of total re-
moval, increased perioperative mortality, and signifi-
cantly lower Karnofsky Performance Status in patients
undergoing repeated surgery (6–8, 12). Some authors
therefore recommend the use of radiotherapy in situations
of recurrence in the absence of immediate risk of optic
nerve compression (11, 23). To address this issue,we com-
pared long-term sequelae associatedwith either radiother-
apy or multiple surgery. In the present cohort, radiother-
apy is associated with a better outcome than multiple
surgery, and this difference was more pronounced for pa-
tients with onset of craniopharyngioma after 1990. How-
ever, the numbers of patients undergoingmultiple surgery
(n 45) or radiotherapy (n 30)were low. Furthermore,
the retrospective nature of the analysis impedes evaluation
of management of recurrence because the choice of treat-
ment reflects the location of the tumor, its intricacy, and
the involvement of adjacent structures. Long-term evalu-
ation of both strategies is needed, ideally through a ran-
domized controlled trial.
Obesity is a major consequence of craniopharyngioma
localization and treatment, and it was seen in 42.6% of
patients in our cohort and in 26 to 80% in earlier studies
(20, 24, 25). Damage to the hypothalamus, either preop-
eratively by the tumor or surgery-related, has been shown
to be the main determinant of obesity, causing increased
food intake through disruption of satiety and reduced en-
ergy expenditure (25–29). Visual impairment, somno-
lence, and vagally mediated hyperinsulinemia have all
been described as contributory factors (29–31). We ob-
served a very high rate of obesity in 67.9%of patientswith
CO less than 10 yr old, compared with 37% in the rest of
the cohort. Other risk factors for later obesity are SIHT,
pterional surgery, and recurrence, all of which were asso-
ciatedwith hypothalamic lesion.Most of our patients had
a normal BMI before surgery but developed rapid post-
operative weight increase. More than half of the patients
presented significant weight gain 1 yr after surgery. A di-
etaryandphysical activityprogramthus formsanessential
part of craniopharyngioma management and should be
implemented immediately after initial surgery in all sub-
jects, including normal-weight patientswith suspected hy-
pothalamic involvement.
Reduced QoL has been reported in both CO and AO
craniopharyngioma (2, 32–34). The largest study to date
comes from the large Kabi International Metabolic Study
database, a cohort treated with recombinant GH of a
pharmaceutical company (2). This study showed that the
score for the Quality of Life Assessment of GHDeficiency
in Adults questionnaire was reduced in all patients and
correlatedwith BMI and age at the onset ofGHdeficit. To
our knowledge, this is the first study to evaluate QoL in a
large sample of unselected patients with CO and AO cra-
niopharyngiomas. In our cohort, all items on the WHO-
QOL BREF questionnaire were reduced in comparison
with a large sample of the French populationwith chronic
diseases, thus confirming the generally poor state of health
of these patients (18). However, items evaluated by the
questionnaire did not significantly correlate with various
clinical traits such as age, gender, tumor size, SIHT, and
tumor management. In particular, QoL was similarly re-
duced in CO and AO patients. However, a self-question-
naire approach is limited for QoL assessment in patients
with craniopharyngiomas because neurocognitive impair-
ment induces misrepresentation and underreporting by
patients, especially in those most severely impaired (35).
In our cohort, radiotherapy was not performed as ad-
juvant therapy after partial resection, but was performed
almost exclusively as an alternative to further surgery on
tumor recurrence.We are thus able to describe the natural
progression of craniopharyngiomas before radiotherapy
and determine risk factors for recurrence in a large subset
of patients with onset after 1990 in whom MRI could be
used to identify residual tumor. It has been reported that
recurrence is frequent, even in the absence of an apparent
residual tumor, usually occurring 2–5 yr after surgery (8,
12, 15, 36, 37).However, recurrence is still possible a long
time after initial treatment, up to 19 yr in our cohort and
up to 36 yr in a previous study (12), thus emphasizing the
need for lifelong follow-up.
Risk of recurrence was associated with SIHT at pre-
sentation. This is consistent with earlier studies in small
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cohorts stating that large lesions causing hydrocephalus
may be associated with an increased recurrence rate (26,
38, 39). Large tumors causing intracranial hypertension
are difficult to resect, and it has been suggested that the
impact on recurrence may actually reflect incomplete re-
section (7). In our study, SIHT remained significantly as-
sociated with a higher risk of recurrence after adjustment
for the presence of a residual tumor, as described by the
radiologist on the imaging 3 to 6 months postoperative,
pointing to the potential for growth of these aggressive
tumors. These findings suggest the importance of close
surveillance in patientswith SIHTat presentation, regard-
less of the confirmation of residual tumor on postopera-
tive imaging.
CO was not associated with risk of recurrence in pre-
vious studies, but one report in patients with childhood
craniopharyngiomas showed that onset before the age of
5 was a significant predictor for recurrence (26). Consid-
ering the median age of 10 yr in CO patients in our cohort
or the previously used cutoff age of 5 yr,we found a higher
rate of recurrence in younger CO patients, although this
was not significant after adjustment for the presence of a
residual tumor. An increased recurrence rate in patients
with onset at a young age is thus probably related to a
higher rate of intracranial hypertension and the presence
of a residual tumor.
No difference between genders in terms of recurrence
was seen in two previous studies (1, 12). In the present
study, male gender appeared to be a significant predictor
of recurrence, even after adjustment for residual tumor. A
higher prevalence of SIHT in male subjects probably ac-
counts for this higher recurrence rate because the relation-
ship between gender and recurrence disappeared after ad-
justment for SIHT.
Conclusions
Despite better outcomes in patients with disease onset
after 1990, craniopharyngioma continues to be associated
with severe sequelae and significant impairment of QoL
and school/work status. Analysis of the published data
shows that the growth rate of craniopharyngiomas varies
considerably between individuals, and consistentmarkers
predicting future relapse are lacking.Our study shows that
onset before the ageof 10yr, SIHTatpresentation, and the
need for pterional surgery constitute independent risk fac-
tors for long-term morbidity and a poor prognosis. Re-
currence is frequent, even where imaging 3–6 months
postoperatively does not identify a residual tumor. SIHT
appears to be themain predictor for later recurrence. In all
cases, patients should undergo multidisciplinary therapy,
including specialized care in neurosurgery, neuroimaging,
endocrinology, nutrition, and neuropsychology.
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